S16-443 Prodrugs of PKC modulators for improved formulation, therapeutic efficacy and tolerability Researchers at Stanford have developed prodrug derivatives of protein kinase C (PKC) modulators that have lower toxicity and are more effective than the parent compound. PKC modulators are being developed to treat a variety of diseases. Paul Wender Nancy Benner Katherine Keenan Jack Sloane Xiaoyu Zang